UK pharma welcomes Brexit Committee focus on transitional arrangements and regulatory relationships

14 January 2017

In December, the UK pharmaceutical industry gave evidence to the Exiting the EU Committee where, though its trade body the Association of the British Pharmaceutical Industry (ABPI), it stated that in the opinion of the UK's £60 billion (~$74 billion) Life Sciences sector, a primary objective for government in Brexit negotiations should be to secure alignment and cooperation with EU medicines regulation.

After reading the Committee's report the ABPI welcomed its explicit focus on the importance of transitional arrangements and relationships with regulatory agencies and bodies. (For further detail and background see here).

ABPI chief executive Mike Thompson comments: “We welcome the Committee's focus on the importance of getting medicine regulation right from day one of the UK leaving the European Union.Securing continued regulatory cooperation and alignment with the EU for medicines will be in the best interests of the UK government, EU member states and patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK